Dhanpat Mohnot, MD
Neurology · Gretna, LANPI 1780689364
Payments from drug & device makers
Across 993 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Promius Pharma LLC$5K
- UCB, Inc.$2K
- Eisai Inc.$2K
- Amgen$891
- Lundbeck LLC$775
- plus $7K from 39 others
What the payments were for
- Consulting fees$4,00016%
- Speaking & faculty fees$3,90015%
- Travel & lodging$1,4976%
- Food & beverage$16,30763%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,751 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $152,826 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 19 | $150,677 |
| UbrelvyUbrogepant | 72 | $101,126 |
| GocovriAmantadine Hcl | 39 | $95,060 |
| IngrezzaValbenazine Tosylate | 12 | $88,866 |
| Nurtec OdtRimegepant Sulfate | 42 | $79,947 |
| QuliptaAtogepant | 60 | $69,469 |
| Emgality PenGalcanezumab-Gnlm | 78 | $64,302 |
| Aimovig AutoinjectorErenumab-Aooe | 68 | $54,826 |
| RytaryCarbidopa/Levodopa | 52 | $53,790 |
| NuplazidPimavanserin Tartrate | 11 | $53,549 |
| BotoxOnabotulinumtoxina | 40 | $51,422 |
| BelsomraSuvorexant | 71 | $46,647 |
| NeuproRotigotine | 28 | $37,078 |
| NourianzIstradefylline | 15 | $36,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox, Linzess | $8,822 | $236,721188 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $712 | $152,82618 claims |
| PfizerNurtec Odt, Zavzpret | $641 | $112,69272 claims |
| MDD US Operations, LLCGocovri | $73 | $95,06039 claims |
| UCB, Inc.Neupro, Briviact | $1,682 | $56,21841 claims |
| Amneal Pharmaceuticals LLCRytary | $57 | $53,79052 claims |
| Acadia Pharmaceuticals IncNuplazid | $16 | $53,54911 claims |
| MerckBelsomra | $34 | $46,64771 claims |
| Kyowa Kirin, Inc.Nourianz | $60 | $36,76615 claims |
| SK Life Science, Inc.Xcopri | $624 | $36,48525 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $660 | $25,40112 claims |
| Eisai Inc.Fycompa | $1,534 | $24,02921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 neurology providers in Louisiana.
Other neurology in Gretna
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
- Bridget BagertNew Orleans$1.4M
- Carol RedillasChalmette$1.3M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Meghan HarrisShreveport$698K
- Maria Carmen WilsonCovington$681K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.